Europe's Largest Gathering for ADC Innovation
As antibody-drug conjugates (ADCs) continue to establish themselves as a cornerstone of modern oncology, breakthrough clinical data, expanding approvals, and significant investment activity are accelerating innovation across the field. As companies race to develop differentiated payloads, novel targets, and next-generation conjugate platforms, understanding the scientific and commercial strategies defining success has never been more important.
Taking place in London from 8-11 March 2027, the 17th World ADC London returns as Europe's largest annual gathering dedicated to the ADC community, bringing together more than 700 leaders from biopharma, biotech, academia, clinical research, and solution providers. The event serves as the industry's annual meeting point to share insights, benchmark progress, form strategic partnerships, and explore the latest advances across ADC development.
The 2027 programme features five dedicated content streams spanning discovery, preclinical and translational development, clinical lessons, process and analytical development, and manufacturing and supply chain. Discussions will focus on overcoming resistance mechanisms, improving response rates, expanding into new patient populations, and advancing differentiated ADC designs capable of becoming future standards of care.
Alongside a world-class speaker faculty, attendees will benefit from extensive networking and partnering opportunities designed to connect the scientists, clinicians, investors, and technology providers shaping the future of the field.
With competition intensifying and innovation accelerating, World ADC London remains the annual orientation point for the European ADC community and a key forum for those looking to stay ahead of the trends, technologies, and partnerships defining the next generation of ADC therapies.
Download the Preliminary Agenda to explore the speakers, companies, scientific breakthroughs, and networking opportunities that will define the next chapter of ADC innovation.
